论文部分内容阅读
目的：观察阿托伐他汀对冠心病患者内酯类物质及肾功能的影响。方法选取济南市长清区人民医院心内科住院的88例冠心病患者为研究对象，按抽签法随机分为两组。两组均给予利尿剂、β受体阻滞剂、血管紧张素转化酶抑制剂等常规药物治疗，观察组在此基础上加服阿托伐他汀20mg ·1次· d－1，疗程1 a。于治疗前和治疗1a末测定比较两组尿蛋白、血肌酐、肾小球滤过率、β2‐微球蛋白、血浆胱抑素水平。采用美国纽约心脏病学会分级方法评估两组心功能改善情况。结果治疗前两组间尿蛋白、血肌酐、肾小球过滤率、β2‐微球蛋白、血浆胱抑素比较无统计学意义（P＞0．05）；治疗后两组间除β2‐微球蛋白比较无统计学意义（P＞0．05），尿蛋白、血肌酐、肾小球滤过率、血浆胱抑素差异均有统计学意义（P＜0．05）；两组内治疗前后比较，除β2‐微球蛋白无显著差异性（P＞0．05），尿蛋白、血肌酐、肾小球滤过率、血浆胱抑素均有统计学意义（P＜0．05）。治疗1a末，观察组心功能改善总有效率90．91％，对照组为72．73％，两组比较差异有显著性（P＜0．05）。结论阿托伐他汀可以提高和改善冠心病患者的心肾功能，提高患者的生存质量。“,”Objective To observe the influence of atorvastatin on lactones and renal function of coronary heart disease (CHD) patient .Methods Eighty‐eight hospitalized CHD patients selected from Dept of Cardiology ,Changqing District People’s Hospital ,Jinan were assigned to research objects and randomly divided into two groups according to lot method .Both groups received such routine pharmacotherapy as di‐uretic ,βreceptor blocker ,angiotensin‐converting enzyme inhibitor and so on ,observation group was plus atorvastatin 20 mg once a day for 1 year .Urine protein ,serum creatinine ,glomerular filtration rate (GFR) ,β2‐microglobulin and plasma cystatin levels of two groups were determined and compared before treatment and at the end of 1 year treatment .Heart function improvements of two groups were assesses u‐sing New York Heart Association (NYHA) class .Results There were no statistical significance in group comparison of urine protein ,serum creatinine ,GFR ,β2‐microglobulin and plasma cystatin before treat‐ment (P>0 .05);after treatment there were statistical significance in group comparison of urine protein , serum creatinine ,GFR and plasma cystatin (P0 .05);there were statistical significance in intragroup pre‐and post‐treatment comparison of urine protein ,serum creatinine , GFR and plasma cystatin (P0 .05) .At the end of 1 year treatment the effective rate of heart function improvement was respectively 90 .91% in observation and 72 .73% in control group ,which showed significant difference (P<0 .05) .Conclusion Atorvastatin could boost and improve heart and renal function of CHD patients and improve patients’ quality of life .